Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate, which is a chemotherapy with a linker (deruxtecan) joined to an antibody (trastuzumab). Trastuzumab binds to a protein found on cancer …
Determinants of sensitivity to HER2-targeted antibody drug ... - Nature
Dec 20, 2025 · In patient-derived urothelial cancer models, the HER2-targeted antibody-drug conjugate (ADC) trastuzumab deruxtecan is significantly more effective than the HER kinase inhibitor neratinib.
FDA fast tracks trastuzumab deruxtecan for HER2+ tumors, including ...
Jan 30, 2024 · The FDA has granted a priority review designation to a supplemental Biologics License Application (sBLA) for trastuzumab deruxtecan (Enhertu) for the treatment of adult patients with …
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients …
May 29, 2024 · Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study.
Breakthroughs in Bladder Cancer: Key Highlights from ASCO GU 2025
Feb 26, 2025 · Antibody Drug Conjugates in Bladder Cancer: The key antibody drug conjugates in metastatic urothelial cancer include enfortumab vedotin, sacituzumab govitecan, trastuzumab …
ASCO GU 2025: HER2 Antibody Drug Conjugate Therapy: A New …
ASCO GU 2025 HER2 antibody drug conjugate therapy, bladder cancer, HER2 alteration incidence, trastuzumab emtansine, disitamab vedotin, metastatic urothelial carcinoma.
Trastuzumab Deruxtecan FDA Approval for HER2-Positive Bladder Cancer ...
May 28, 2024 · Unlike these, trastuzumab deruxtecan is for a subset of patients with IHC 3+ tumors, less than 15% of advanced UC patients, and is available only in later-line therapy. While it may not affect …
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors …
Introduction: DESTINY-PanTumor02 (NCT04482309) evaluated the efficacy and safety of trastuzumab deruxtecan (T-DXd) in pretreated patients with human epidermal growth factor receptor 2 (HER2) …
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing ...
This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors. This study …
Updated EAU Guidelines Transform Bladder Cancer Management
Jun 29, 2025 · In the metastatic context, trastuzumab deruxtecan is newly recommended for HER2-positive patients, while sacituzumab govitecan has been removed following withdrawal of FDA approval.